Enanta Pharmaceuticals, Inc. (ENTA)
-NasdaqGS 19.86 
0.20(1.00%) 3:59PM EDT
| Prev Close: | 20.06 |
|---|
| Open: | 20.19 |
|---|
| Bid: | 14.25 x 100 |
|---|
| Ask: | 29.00 x 200 |
|---|
| 1y Target Est: | 26.75 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 19.70 - 20.19 |
|---|
| 52wk Range: | 14.31 - 22.40 |
|---|
| Volume: | 19,732 |
|---|
| Avg Vol (3m): | 105,273 |
|---|
| Market Cap: | 43.53M |
|---|
| P/E (ttm): | 100.30 |
|---|
| EPS (ttm): | 0.20 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- ENANTA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, May 14)
- Enanta Pharmaceuticals Announces Financial Results for the Second Fiscal Quarter and Six Months Ended March 31, 2013Business Wire(Wed, May 8)
- ENANTA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements anEDGAR Online(Wed, May 8)
- Breakthrough Therapy Designation from the U.S. Food and Drug Administration Granted to Investigational HCV Regimen Containing Protease Inhibitor ABT-450Business Wire(Mon, May 6)
- In Development-Stage Biotechs, Success Comes Down to One Asset: Expert Analyst Boris Peaker Discusses the Competitive Biotechnology Environment with The Wall Street TranscriptWall Street Transcript(Wed, May 1)
- Enanta Pharmaceuticals announces data from Phase 2b study related to ABT-450theflyonthewall.com(Tue, Apr 23)
- Enanta Announces New Data From Phase 2b Interferon-Free Combination Studies with Protease Inhibitor ABT-450 for Hepatitis C Treatment to be Presented at EASLBusiness Wire(Tue, Apr 23)
- 3 Stocks With Upgrades That Moved Against the Market on Mondayat Motley Fool(Wed, Apr 17)
- 3 Biotechs With Recent Intensive Insider Buyingat Seeking Alpha(Sun, Apr 7)
- Reviewing 6 Recent IPO Transactionsat Seeking Alpha(Fri, Apr 5)
- Big IPOs Had Good Q1, But VC-Backed Growth Plays LaggedInvestor's Business Daily(Mon, Apr 1)
- ENANTA PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, FinanEDGAR Online(Thu, Mar 28)
- Enanta Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Underwriters’ Over-Allotment OptionBusiness Wire(Tue, Mar 26)
- 7 Stocks That Dared to Go Public Last Weekat Motley Fool(Tue, Mar 26)
- U.S. IPO Weekly Recap: 7 Deals Price, 6 New Filersat Seeking Alpha(Mon, Mar 25)
Key Statistics
| Forward P/E (1 yr): | 39.72 |
|---|
| P/S (ttm): | 1.31 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Sep-13)
: | 0.11 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.34 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Enanta Pharmaceuticals, Inc., a biotechnology company, engages in the development of small molecule drugs for the infectious disease areas. Its product candidates include ABT-450, an inhibitor of NS3 protease that is in Phase III clinical trials f...
View More